Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft (Protocol DPRC Array)

This study has been terminated.
(The number of included patients is sufficient.)
Sponsor:
Information provided by:
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT00746057
First received: September 2, 2008
Last updated: September 27, 2013
Last verified: September 2013

September 2, 2008
September 27, 2013
May 2006
May 2011   (final data collection date for primary outcome measure)
Transcriptional profile (exhaustive DNAchip) on the blood at 3 months post transplantation. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00746057 on ClinicalTrials.gov Archive Site
Correlation of the transcriptional profile at 3 months after transplantation with histological features of the kidney graft at one year of follow-up. [ Time Frame: One year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft (Protocol DPRC Array)
Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft.

The aim of the study is to explore the possibility to identify, at an early stage after a renal graft and from blood samples collected within first months after graft, a predictive transcriptional profile of long term occurence of graft operational tolerance or chronic rejection.

The aim of the study is to determine an early transcriptional profile of chronic rejection in the transcriptome of mononuclear blood cells. Validation and predictivity of transcriptional analysis will be based on graft function and graft histology one year after transplantation.The other aim is to determine an early transcriptional profile of operational tolerance in the same patients using a DNA chip dedicated including two lists of genes discriminating tolerant patients who are stopped immunosuppressant treatment for over a year.

To allow statistical analysis of 100 patients followed one year after graft, patients not assessable at one year due to early termination of study will be replaced.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
First Cadaveric Renal Graft
Biological: DNA chip
One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
1
Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
Intervention: Biological: DNA chip
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
134
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients aged 18 to 65 years old,
  • Donor's age ≤ 60 years old,
  • Patients receiving a first cadaveric renal graft,
  • Patients taking immunosuppressant treatment including an induction with Simulect at day 0 and day 4, FK 506 (Prograf®) associated with Cellcept and steroids (for three months),
  • Patients don't taking indispensable anticoagulant treatment.

Exclusion Criteria:

  • Patient's age < 18 or > 65 years old,
  • Donor's age ≥ 60 years old,
  • Pregnant women or breast feeding women,
  • Patients receiving a retransplantation, a kidney and pancreas graft or a graft from a living donor,
  • Patients taking immunosuppressant treatment without FK 506 (Prograf®), Cellcept and steroids.
  • Patients with coagulation troubles or taking indispensable anticoagulant treatment,
  • No biopsy before graft.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00746057
06/2-E
No
Not Provided
Nantes University Hospital
Not Provided
Principal Investigator: Jean-Paul SOULILLOU, Professor CHU Nantes
Study Chair: Magali GIRAL, Doctor CHU Nantes
Study Chair: Maryvonne HOURMANT, Professor CHU Nantes
Study Chair: Diego CANTAROVICH, Doctor CHU Nantes
Study Chair: Jacques DANTAL, Professor CHU Nantes
Study Chair: Gilles BLANCHO, Professor CHU Nantes
Study Chair: Aurélie MEURETTE, Doctor CHU Nantes
Study Chair: Marie LINO, Doctor CHU Nantes
Study Chair: Georges MOURAD, Professor University Hospital, Montpellier
Study Chair: Lionel ROSTAING, Professor CHU Toulouse
Study Chair: Dominique DURAND, Professor CHU Toulouse
Study Chair: Christophe LEGENDRE, Professor AP-HP (Hôpital Necker)
Study Chair: Michèle KESSLER, Professor CHU Nancy
Study Chair: Emmanuel MORELON, Professor CHU Lyon
Study Chair: Sameh DAOUD, Doctor CHU Lyon
Study Chair: Cécile CHAUVET, Doctor CHU Lyon
Study Chair: Olivier THAUNAT, Doctor CHU Lyon
Study Chair: Jean-François SUBRA, Professor University Hospital, Angers
Study Chair: François BAYLE, Doctor CHU Grenoble
Study Chair: Elisabeth CASSUTO, Doctor CHU Nice
Nantes University Hospital
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP